Alaunos Therapeutics (TCRT) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $1.9 million.
- Alaunos Therapeutics' Cash & Equivalents rose 1515.15% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 1515.15%. This contributed to the annual value of $1.1 million for FY2024, which is 8200.26% down from last year.
- Per Alaunos Therapeutics' latest filing, its Cash & Equivalents stood at $1.9 million for Q3 2025, which was up 1515.15% from $2.9 million recorded in Q2 2025.
- In the past 5 years, Alaunos Therapeutics' Cash & Equivalents registered a high of $100.1 million during Q1 2021, and its lowest value of $319000.0 during Q1 2025.
- In the last 5 years, Alaunos Therapeutics' Cash & Equivalents had a median value of $18.3 million in 2023 and averaged $32.8 million.
- Over the last 5 years, Alaunos Therapeutics' Cash & Equivalents had its largest YoY gain of 1689.0% in 2025, and its largest YoY loss of 9230.4% in 2025.
- Alaunos Therapeutics' Cash & Equivalents (Quarter) stood at $76.1 million in 2021, then crashed by 48.64% to $39.1 million in 2022, then plummeted by 84.48% to $6.1 million in 2023, then plummeted by 82.0% to $1.1 million in 2024, then skyrocketed by 77.64% to $1.9 million in 2025.
- Its Cash & Equivalents was $1.9 million in Q3 2025, compared to $2.9 million in Q2 2025 and $319000.0 in Q1 2025.